Tevogen rises as AI platform upgrade boosts drug discovery push

Tevogen

13/03/2026 16:43

** Shares of biotech firm Tevogen Bio TVGN.O rise as much as 7.9% to $6.87 in afternoon trading

** Co says its Tevogen.AI platform improved accuracy in predicting drug targets most likely to work in patients, helping cut trial-and-error in drug development

** Platform now analyzes more than 655 mln peptide sequences from about 24 mln proteins, drawing on data from 37 mln scientific papers, co says

** TVGN adds its PredicTcell model lifted recall to 92% from 87% and precision to 48% from 40% in recent tests

** Says it is seeking partnerships with drugmakers to advance select peptide candidates across cancer, virus and brain disease programs

** Shares down ~68% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))